Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ⅱ Clinical Trial of CNCT19 Cell Injection in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT04684147 is registered in ClinicalTrials.gov with Juventas Cell Therapy Ltd. as lead sponsor.

NCT NCT04684147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04684147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ⅱ Clinical Trial of CNCT19 Cell Injection in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Lead sponsor
Juventas Cell Therapy Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
December 24, 2020
Completion date
December 31, 2026
Enrollment
100 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory acute lymphoblastic leukemia